Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

Contributed by: Business Wire

Logo

Tags

Health

Genetics

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Ajinomoto Co., Inc. to Acquire Forge Biologics

More Like This

Forge Biologics Announces the FUEL™ AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production

Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production

Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation

Merck operators monitoring viral vector production in a bioreactor in Merck's Carlsbad, California manufacturing facility. (Photo: Business Wire)

Merck Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing

PR Newswire associated0

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

BeiGene's flagship biologics manufacturing facility and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J., is seen. (Photo: Business Wire)

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering